Pipeline review

DRUG NAME/ MANUFACTURER PROPOSED USE HOW IT WORKS WHAT’S IMPORTANT
aducanumab / Biogen/Eisai Alzheimer's disease Monoclonal antibody for the treatment of Alzheimer's disease that targets beta amyloid.  One of the pathological hallmarks of Alzheimer's disease are beta amyloid plaques which cause atrophy of the brain and surrounding blood vessels. Route of administration: Intravenous infusion
Benefit coverage: Medical, Specialty
Anticipated FDA decision: 3/7/2021
Cost Estimate: $50,000-$100,000 per patient per year
idecabtagene vicleucel (Ide-cel) / Bluebird Bio/Bristol Myers Squibb Multiple myeloma CAR-T therapy for treatment of patients with relapsed or refractory aggressive large B-cell non-Hodgkin lymphoma.  One time IV infusion of the patient's own genetically modified T-cells. Route of administration: Intravenous infusion
Benefit coverage: Medical, Specialty
Anticipated FDA decision: 3/29/2021
Cost Estimate: $475,000 per patient
lisocabtagene maraleucel (Breyanzi) /
Bristol Myers Squibb
Non-Hodgkin lymphoma CAR-T therapy for treatment of patients with relapsed or refractory aggressive large B-cell non-Hodgkin lymphoma. One or 2 intravenous infusions. Route of administration: Intravenous infusion
Benefit coverage: Medical, Specialty
Anticipated FDA decision: 11/16/2020
Cost Estimate: $373,000 per treatment per patient
tralokinumab /
(LEO Pharma)
Atopic dermatitis Anti-interleukin-13 for the treatment of moderate to severe atopic dermatitis.  Atopic dermatitis (AD) is a chronic skin disease characterized by inflammation of the skin and skin
barrier defects.
Route of administration: Subuctaneous injection (every 2 weeks)
Benefit coverage: Pharmacy, Specialty
Anticipated FDA decision: 4/27/2021
Cost Estimate: $40,000 per patient per year
vericiguat /
Bayer/Merck
Chronic heart failure Soluble guanylate cyclase stimulator for oral use in combination with other heart failure therapies to reduce the risk of cardiovascular death and heart failure hospitalization. Route of administration: Oral
Benefit coverage: Pharmacy
Anticipated FDA decision: 1/20/2021
Cost Estimate: Unknown
viloxazine /
Supernus
Attention-deficit hyperactive disorder (ADHD) Non-stimulant medication to treat ADHD Route of administration: Oral
Benefit coverage: Pharmacy
Anticipated FDA decision: 11/8/2020
Estimated 2024 Global Annual Sales (millions): $142

Notes:
Benefit coverage is based on currently available information and could change pending final FDA-approved prescribing information.

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and complete details of prescription drug coverage, contact a Cigna representative.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Cigna Behavioral Health, Inc., Cigna Health Management, Inc., Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.

© 2020 Cigna. All rights reserved